Media stories about Imprimis Pharmaceuticals (NASDAQ:IMMY) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Imprimis Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 46.808875896535 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Separately, ValuEngine raised shares of Imprimis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd.
IMMY traded down $0.03 on Wednesday, hitting $2.42. 79,011 shares of the company’s stock were exchanged, compared to its average volume of 308,202. Imprimis Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $3.55. The company has a quick ratio of 0.91, a current ratio of 1.25 and a debt-to-equity ratio of 180.00.
Imprimis Pharmaceuticals Company Profile
Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.